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Summary
 Background Primary cardiac malignancies are uncommon, with an estimated autopsy inci-
dence of 0.001– 0.05%, and the vast majority of malignancies involving the heart 
and pericardium are metastatic. Three quarters of these tumours are benign, and 
approximately half of adult cardiac tumours are myxomas. Rhabdomyomas, pap-
illary ﬁ broelastomas, lipomas, ﬁ bromas, and haemangiomas are the other benign 
tumours. Rhabdomyomas are also the most common paediatric primary cardiac 
tumours. Primary malignant cardiac malignancies make up one fourth of all car-
diac tumours, and angiosarcoma, rhabdomyosarcoma, ﬁ brosarcoma, leiomyosar-
coma, malignant ﬁ brous histiocytoma, pericardial mesothelioma and lymphoma 
are the major neoplasms. The diagnosis is often made by transthoracic echocar-
diography (TTE) but magnetic resonance imaging (MRI) and computed tom-
ography (CT) are needed to determine the characterization, location and ex-
tent of cardiac and paracardiac masses. These imaging modalities are also used 
for both treatment planning and post-treatment follow-up.
 Aim In this report, we evaluate primary cardiac benign and malignant tumours and 
metastatic lesions with the treatment strategies by reviewing the recent litera-
ture.
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BACKGROUND
The vast majority of malignancies involving the 
heart and pericardium are metastatic, and prima-
ry tumours are rare, with an autopsy incidence 
of 0.001–0.05% [1,2]. Most primary cardiac tu-
mours are benign, and nearly three quarters of 
these tumours are myxomas. Rhabdomyoma, 
lipoma, ﬁ broma, teratoma, haemangioma and 
ﬁ broelastoma are the other benign neoplasms. 
Primary malignant cardiac malignancies make 
up one fourth of all cardiac tumours, and angi-
osarcoma, rhabdomyosarcoma, ﬁ brosarcoma, 
leiomyosarcoma, malignant ﬁ brous histiocyto-
ma, pericardial mesothelioma and lymphoma 
are the major neoplasms. Most of both primary 
benign and malignant cardiac tumours originate 
from the atria [3–5].
AIM
Intracardiac obstruction and systemic embolisa-
tion ﬁ ndings and other systemic signs are general-
ly present in most patients, and echocardiography, 
computed tomography (CT), magnetic resonance 
imaging (MRI) and whole body gallium scans are 
used for preoperative diagnosis [6].
II. CLINICAL FEATURES
Having a suspicion of a primary cardiac tumour 
is imperative in establishing the diagnosis since 
presenting symptoms can often mimic other non-
neoplastic cardiac pathology. There are sever-
al clinical features but the classic triad includes 
signs resulting from intracardiac obstruction and 
systemic embolisation and other systemic symp-
toms [7,8]. Large atrial tumours may obstruct 
atrioventricular ﬂ ow and mimic valvar stenosis. 
The main difference from classic valvar stenosis 
is that the symptoms caused by the tumour are 
paradoxical and may change with the patient’s 
body position.
Embolisation is also a frequent ﬁ nding since ei-
ther the tumour itself or adherent thrombus may 
migrate. These emboli may mimic endocarditis 
or vasculitis and cause cerebrovascular events. 
Pulmonary venous hypertension and pulmonary 
oedema can occur due to either embolisation or 
obstruction and cause right heart failure. In such 
cases dyspnoea and orthopnoea are the common-
est symptoms. Cardiac tamponade due to right 
heart failure is also a frequent ﬁ nding. The oth-
er ﬁ ndings are syncope, haemoptysis, claudica-
tion and angina. The symptoms such as weight 
loss, fever and fatigue that can also be present 
in infective endocarditis, vasculitis or other ma-
lignancies can raise difﬁ culties in establishing 
the diagnosis. Arrhythmias such as atrioventricu-
lar block or ventricular tachycardia are frequent 
and may be the preceding symptoms of a cardi-
ac tumour [7,8].
However, about 80% of primary malign cardiac 
malignancies present with systemic metastases so 
early diagnosis is hard to establish [9].
III. BENIGN CARDIAC TUMOURS
A. Myxomas
Cardiac myxoma is the most common cardiac tu-
mour in adults. Comprising 50% of all cardiac ma-
lignancies, it is more common in women, and the 
median age at diagnosis is 50. 75% of myxomas 
are left atrial and are mainly located in the atrial 
fossa ovalis region. Complex cardiac myxomas are 
part of a familial autosomal dominant inherited 
disease and can be seen in younger ages. In such 
cases, myxomas are associated with at least two 
or more lesions such as cutaneous lentiginosis, 
at least one cutaneous myxoma, primary adren-
ocortical micronodular dysplasia with Cushing’s 
syndrome, testicular tumours (large-cell Sertoli-
cell tumours), pituitary adenomas, and myxoid 
ﬁ broadenomas of the breast [10].
They can also be part of syndromes like LAMB 
(atrial myxoma, lentigines, mucocutaneous myxo-
ma, blue naevi) and NAME (atrial myxoma, nae-
vi, myxoid neuroﬁ bromata, ephelides). Carney 
complex is the general name of these syndromes 
and the PRKAR1A germline mutation (gene de-
letion at the 17q2 locus) is associated with them 
[11].
Both cardiac and systemic symptoms such as dys-
pnoea, orthopnoea, syncope, fever, weight loss 
and haemoptysis can be present. Embolisation 
is also a major problem and multiple emboli can 
mimic infective endocarditis or vasculitis with ma-
jor complications of cerebrovascular events and 
sudden death [10]. Right-side located tumours 
can embolise to the lungs, resulting in pulmo-
nary hypertension. In such cases, murmurs are 
frequently present.
Diagnosis depends on a high index of suspi-
cion, since signs and symptoms such as cachex-
ia, fever, arthralgias, transient ischaemic attacks, 
stroke, murmurs, anaemia, raised acute phase 
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reactants , and erythrocyte sedimentation rate 
are also frequently found in other cardiac or in-
fectious diseases, vasculitis or other malignancies 
[10]. Echocardiography is the main diagnostic 
tool and in most cases it is sufﬁ cient to verify the 
diagnosis. Cardiac embolisation or in situ throm-
bus is the main disease that must be considered 
in differential diagnosis especially in right atri-
al myxomas and in such cases the use of oral an-
ticoagulants for a short period and observing if 
there is shrinkage in the lesion may be useful. If 
the confusion persists, MRI can be performed 
for further evaluation [12].
Early surgical resection is the main treatment 
strategy for especially large atrial myxomas since 
although these tumours are histologically benign, 
embolisation, obstruction or cardiac arrhythmi-
as can be fatal. The goal of surgery is resecting 
the tumoural lesion with sufﬁ cient margins and 
this goal is achievable in most cases. Following 
successful surgery the prognosis is excellent, but 
there is always a small risk of local recurrence so 
close follow-up with echocardiography is of great 
importance [13].
B. Rhabdomyoma
Rhabdomyoma is the most common benign car-
diac tumour in childhood and is associated with 
tuberous sclerosis in most cases. These tumours 
are also characteristically multiple and ventricu-
lar. Since spontaneous tumour resolution is com-
mon, surgical resection is performed only in pa-
tients with life-threatening complications and 
treatment is usually conservative. In patients who 
need surgery for a rhabdomyoma, subtotal exci-
sion to preserve surrounding structures may be 
reasonable, with the expectation of further sta-
bility or resolution [14,15].
C. Papillary ﬁ broelastoma
The real incidence of papillary ﬁ broelostomas is 
unknown since in most cases these tumours are si-
lent and they are incidentally found in autopsies. 
Furthermore, most of the excised valves are not 
sectioned and many of the small tumours are pos-
sibly missed. Also these tumours can be mistaken 
for valvar vegetations. Most of the lesions are locat-
ed on the valvular endocardium of the aortic and 
mitral valves, and the “sea anemone” appearance, 
with a short attaching pedicle, is typical [16].
Recent studies have shown that there is a high 
incidence of embolisation of cerebral and coro-
nary arteries, and parallel to these ﬁ ndings clini-
cally cerebrovascular and cardiac ischaemic events 
and sudden death are not infrequent. Regarding 
these facts, surgical resection is now considered 
more appropriate for these lesions but wider re-
sections may require valvar replacement. The 
need for surgery should be weighed against the 
morbidity in such cases [17].
D. Haemangioma
Haemangiomas are benign vascular tumours that 
generally occur in the interventricular septum. 
Representing approximately 1–2% of heart tu-
mours, they also arise from the epicardium and 
myocardium. They are mostly diagnosed in the 
fourth to ﬁ fth decades and are more frequent in 
males. “Tumour blush” is characteristic in cor-
onary angiography. Since these lesions have a 
highly vascular nature, surgical excision is not 
generally possible and close follow-up is indi-
cated [18].
E. Fibroma
Cardiac ﬁ bromas are low-grade tumours that are 
generally interventricular and typically they are 
seen in childhood. The median age at presenta-
tion is 13 years; however, one third of these tu-
mours are seen in children younger than 1 year 
old. The major complications are arrhythmias, 
syncope, heart failure and sudden death [18]. 
The diagnosis can be made with ﬂ uoroscopy 
since there are multiple foci of calciﬁ cation in 
the tumour. In small tumours total surgical ex-
cision can be performed but tumours with large 
dimensions may even require cardiac transplan-
tation [19].
F. Lipoma and lipomatous hypertrophy
Lipomas are generally asymptomatic tumours 
that are usually subpericardially located and they 
constitute about 7–10% of primary cardiac ne-
oplasms. These tumours are generally small but 
occasionally they become large and extend into 
the left atrial cavity, resulting in arrhythmias. The 
diagnosis can be made by MRI [20].
Lipomatous hypertrophy of the interatrial septum 
is the accumulation of fat in the interatrial septum. 
It is common in obese patients and can occasion-
ally cause atrial arrhythmias. Diagnosis depends 
on establishing the presence of thickening in the 
atrial septum by ultrasonography or MRI. Weight 
loss may be beneﬁ cial in some cases [18].
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G. Cystic tumour of the atrioventricular node
The cystic tumour of the atrioventricular node is 
a small lesion located at the base of the atrial sep-
tum in the region of the atrioventricular node. 
It is a very rare benign tumour and in most cases 
asymptomatic, but it has great importance since 
these tumours are the smallest tumours that can 
lead to sudden and unexpected death. The ma-
jority of these cysts are diagnosed during the au-
topsies of people who have died suddenly [18].
IV. MALIGNANT CARDIAC TUMOURS
A. Angiosarcoma
Angiosarcomas are the most common malign 
cardiac tumours, constituting about one third of 
all primary cardiac neoplasms. The vast majori-
ty are located in the right atrium and are most-
ly seen in men between the third and ﬁ fth dec-
ades. Cardiac signs such as pericardial effusion, 
chest pain, and arrhythmias can be seen as well 
as systemic ﬁ ndings such as weight loss, fatigue 
and fever. Systemic metastases develop in most 
patients and the lung is the most common met-
astatic organ, followed by bone and brain. Local 
invasion of the epicardium and endocardium, 
intracavitary extension and local spread to pleu-
ra and mediastium are also frequent. Diagnosis 
is made by echocardiography or MRI showing 
a right atrial mass. Prognosis is very poor (3–6 
months following diagnosis) and there is no ef-
fective systemic treatment [18,21].
B. Rhabdomyosarcoma
Rhabdomyosarcomas are rare tumours with non-
speciﬁ c cardiac symptoms and distal embolisation. 
These tumours can be bulky but unlike angiosa-
rcomas they rarely inﬁ ltrate beyond the parietal 
pericardium. A good response to chemothera-
py is reported in only some cases and survival is 
quite poor [22].
C. Osteosarcoma
Osteosarcoma constitutes 5–10% of cardiac sarco-
mas. They are generally located in the left atrium 
and can grow to large dimensions. These tumours 
are histologically heterogeneous and ﬁ brosarco-
ma or malignant ﬁ brous histiocytoma foci can ac-
company osteosarcoma cells. Cardiac symptoms 
are the major ﬁ ndings and distant metastases can 
occur in an important part/occur in a large pro-
portion of the patients. Prognosis is poor [23].
D. Leimyosarcoma
These very rare tumours (<1%) are highly inva-
sive and can cause arrhythmias, atrioventricular 
blocks, dyspnoea, chest pain, right heart failure 
and sudden death. They are also usually locat-
ed in the left atrium and like other sarcomas 
there is no effective treatment and a poor sur-
vival rate [24].
E. Other sarcomas
Fibrosarcomas, liposarcomas, undifferentiat-
ed sarcomas and malignant ﬁ brous histiocyto-
mas are the other primary cardiac sarcomas. 
Fibrosarcomas and histiocytomas can be multi-
ple and characteristically all of them can invade 
all cardiac chambers and pericardium. Prognoses 
are poor [24].
F. Treatment strategies for cardiac sarcomas
The outcome of cardiac sarcomas is very poor 
with a median survival of less than 1 year and 
long-term survival less than 15% [25].
Since patients who undergo complete excision 
have the possibility of a cure, the goal of surgery 
is excision of the tumoural lesion with clear mar-
gins. However, this can be achieved only in a small 
proportion of the tumours because of the ana-
tomical and surgical limitations. In such cases re-
peated re-excisions in an attempt to control the 
symptoms of local progression can be made since 
the efﬁ cacy of chemotherapy and radiotherapy 
in delaying local progression of residual disease 
is unknown [25,26]. There is limited evidence 
showing that patients can beneﬁ t from cardiac 
transplantation since even low-grade sarcomas 
have the potential of early systemic metastasis, 
so this approach remains controversial.
Postoperative radiotherapy following complete 
resection has the potential to reduce local re-
currence rate, but a radical dose cannot be giv-
en to the heart because of the high risk of radi-
ation cardiomyopathy and pericarditis, which 
can be fatal. Therefore only low dose radiother-
apy can be safely used in a pre- or postoperative 
setting [27].
The use of chemotherapy shows no signiﬁ cant 
beneﬁ cial effect on survival for cardiac sarco-
mas and can be used only for cytoreduction be-
fore surgery or for palliation of unresectable dis-
ease [28].
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G. Primary cardiac lymphomas
The term primary cardiac lymphoma is used for 
lymphomas with the absence of disease outside 
the heart and/or pericardium and the presence 
of cardiac lymphatic inﬁ ltration at the time of 
initial diagnosis. These tumours have histori-
cally been very rare tumours but parallel to the 
growing incidence of AIDS (acquired immun-
odeﬁ ciency syndrome) and organ transplanta-
tions the incidence of cardiac lymphomas has 
also increased. B-cell lymphomas (follicle cen-
tre-cell lymphomas, immunoblastic lymphomas, 
diffuse large-cell lymphomas, and Burkitt’s lym-
phoma) are the major histological types and 
they generally present with arrhythmias, cardi-
ac failure or tamponade. Surgery, chemothera-
py and radiotherapy can be used for treatment 
but the response is limited and the prognosis is 
poor [29].
V. CARDIAC METASTASES
The incidence of cardiac metastases is about 
10% and they are about 20 times more com-
mon than primary cardiac neoplasms [30]. 
However, a large proportion of the metastatic 
lesions are silent and they are generally found 
in autopsies. These lesions are usually epicar-
dial but can also be myocardial or endocardial. 
Malign melanoma is the major tumour that me-
tastasizes to the heart since 50% of melanoma 
patients are found to have cardiac metastases 
during the autopsies [31]. Germ cell tumours 
and malign melanoma also have a high rate of 
metastasis to the heart. Leukaemias and lym-
phomas are also commonly associated with car-
diac metastasis.
There are four major paths for cardiac me-
tastasis: local invasion (mediastinal tumours 
such as lung, breast cancer), haematogenous 
spread, lymphatic spread and extension from 
the inferior vena cava (renal cell carcinoma) 
[32].
Metastases to the heart or pericardium from the 
other common tumours such as lung, breast, co-
lon-rectum, liver or cervix cancers are also rare-
ly reported.
Although the great majority are silent, in some 
cases pericardial effusion or cardiac tampon-
ade may be the ﬁ rst signs of cardiac metastas-
es. Arrhythmias, tachycardia or heart failure can 
also develop and in some cases be fatal [33].
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